L'intérêt à découvert pour ICU Medical donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de ICU Medical. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

ICU Medical (NASDAQ:ICUI) Stock, Rapport sur les intérêts à découvert

ICU Medical

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

ICU Medical Inc

Raymond James analyst Jayson Bedford maintains ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Strong Buy and lowers the price target from $197 to $187.

News

Price Target

Analyst Ratings

ICUI

Raymond James Maintains Strong Buy on ICU Medical, Lowers Price Target to $187

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.28 by 34.37 percent. This is a 79.17 percent increase over earnings of $0.96 per share from the same period last year. The company reported quarterly sales of $604.70 million which beat the analyst consensus estimate of $570.12 million by 6.07 percent. This is a 6.71 percent increase over sales of $566.65 million the same period last year.

Earnings

Earnings Beats

ICU Medical Q1 Adj. EPS $1.72 Beats $1.28 Estimate, Sales $604.70M Beat $570.12M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Keybanc analyst Tim Rezvan maintains ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Overweight and lowers the price target from $209 to $191.

Keybanc Maintains Overweight on ICU Medical, Lowers Price Target to $191

Needham analyst Mike Matson reiterates ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on ICU Medicalto Hold

<a href="https://www.icumed.com/">ICU Medical Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), a worldwide leader in the development, manufacture and sale of innovative medical devices, has announced 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Solo&#x2122; precision IV pump, a single-channel complement to the dual-channel Plum Duo&#x2122;. ICU Medical also received 510(k) clearance for updated versions of the Plum Duo precision IV pump and LifeShield&#x2122; infusion safety software, completing the initial launch of the <a href="https://www.icumed.com/landing-pages/iv-performance-platform/">ICU Medical IV Performance Platform</a>. With these FDA clearances, ICU Medical is introducing its <a href="https://www.icumed.com/about-us/clinical-connections/introducing-precision-infusion-pumps/">new category of precision IV pumps</a> and expanding the ICU Medical IV Performance Platform.
Unlike traditional pumps that rely on specific setups and conditions for accurate delivery, precision IV pumps are designed to address delivery variability while supporting the increasing need for accurate data in modern patient care. Built on the unique cassette technology in the <a href="https://www.icumed.com/products/infusion-therapy/infusion-pumps-and-software/plum-large-volume-pumps/plum-360-large-volume-infusion-pump/">Best in KLAS award-winning Plum 360&#x2122;</a>, the <a href="https://www.icumed.com/products/infusion-therapy/infusion-pumps-and-software/plum-large-volume-pumps/plum-precision-iv-pumps/">Plum Solo and Plum Duo precision IV pumps</a> deliver ±3% accuracy in real-world conditions and eliminate the infusion inconsistencies found in traditional pumps, providing clinicians with predictable performance and reliable infusion documentation.

Government

Regulations

ICU Medical Gets FDA Green Light for New Precision IV Pumps, Launches Solo and Duo Models

WIIM

ICU Medical shares are trading lower. The company reported Q4 financial results.

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) is looking for FY2025 Adj EPS of $6.55-$7.25 vs $7.13 analyst estimate..

Guidance

ICU Medical Sees FY2025 Adj EPS $6.55-$7.25 vs $7.13 Est

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) is looking for FY2025 GAAP EPS of $(1.81)-$(1.11) vs $0.22 analyst estimate..

ICU Medical Sees FY2025 GAAP EPS $(1.81)-$(1.11) vs $0.22 Est

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) reported quarterly earnings of $2.11 per share which beat the analyst consensus estimate of $1.48 by 42.57 percent. This is a 34.39 percent increase over earnings of $1.57 per share from the same period last year. The company reported quarterly sales of $629.80 million which beat the analyst consensus estimate of $593.86 million by 6.05 percent. This is a 7.14 percent increase over sales of $587.86 million the same period last year.

ICU Medical Q4 Adj EPS $2.11 Beats $1.48 Estimate, Sales $629.80M Beat $593.86M Estimate

AAON

ACEL

ACHC

ACHR

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARRY

AUPH

BBWI

BCSF

BECN

BWMX

CABO

CDXS

CLCO

CLOV

CMBT

CMLS

CODI

CRDF

CSTL

CUBE

CVEO

CYTK

DAIO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

In the preceding three months, 4 analysts have released ratings for ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $197.5, along with a high estimate of $209.00 and a low estimate of $183.00. This current average has increased by 14.49% from the previous average price target of $172.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733947242_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive ICU Medical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$198.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$183.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ICU Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ICU Medical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ICU Medical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ICU Medical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICU Medical analyst ratings.</a>
<h2>Delving into ICU Medical's Background</h2>
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
<h3>Understanding the Numbers: ICU Medical's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, ICU Medical showcased positive performance, achieving a revenue growth rate of 6.47% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ICU Medical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.6%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ICU Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ICU Medical's ROA excels beyond industry benchmarks, reaching -0.77%. This signifies efficient management of assets and strong financial health.
Debt Management: ICU Medical's debt-to-equity ratio is below the industry average. With a ratio of 0.81, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On ICU Medical Through 4 Analysts

Jefferies analyst Michael Toomey upgrades ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) from Hold to Buy and announces $200 price target.

Upgrades

Jefferies Upgrades ICU Medical to Buy, Announces $200 Price Target

During the last three months, 4 analysts shared their evaluations of ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $195.0, a high estimate of $209.00, and a low estimate of $183.00. This upward trend is apparent, with the current average reflecting a 16.3% increase from the previous average price target of $167.67.
<img src="https://www.benzinga.com/files/images/story/2024/1731513647_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of ICU Medical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$198.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$183.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$158.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ICU Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ICU Medical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ICU Medical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICU Medical analyst ratings.</a>
<h2>Delving into ICU Medical's Background</h2>
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
<h3>ICU Medical: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, ICU Medical showcased positive performance, achieving a revenue growth rate of 8.58% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ICU Medical's net margin excels beyond industry benchmarks, reaching -3.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ICU Medical's ROE excels beyond industry benchmarks, reaching -1.04%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ICU Medical's ROA stands out, surpassing industry averages. With an impressive ROA of -0.5%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: ICU Medical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.82.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down ICU Medical: 4 Analysts Share Their Views

Keybanc analyst Brett Fishbin maintains ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Overweight and raises the price target from $198 to $209.

Keybanc Maintains Overweight on ICU Medical, Raises Price Target to $209

Needham analyst Mike Matson reiterates ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Hold.

Needham Reiterates Hold on ICU Medical

The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market.
<ul>
<li>Joint venture becomes part of a global manufacturing network with scale and redundancy</li>
<li>Intends to add long-term supply resiliency and accelerate IV solutions new product development in North America</li>
<li>Combines Otsuka Pharmaceutical Factory, Inc.'s expertise and global manufacturing scale with ICU Medical's strong North American production and distribution</li>
<li>ICU Medical to provide commercial services to the joint venture</li>
<li>Expected to become operationally effective in early Q2 2025</li>
<li>Full presentation available for view <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4300832-1&amp;h=1684507301&amp;u=https%3A%2F%2Fir.icumed.com%2Fpresentations&amp;a=here">here</a></li>
</ul>
SAN CLEMENTE, Calif. and TOKUSHIMA, Japan, Nov. 12, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4300832-1&amp;h=3638334367&amp;u=https%3A%2F%2Fwww.icumed.com%2F&amp;a=ICU+Medical%2C+Inc.">ICU Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), a worldwide leader in the development, manufacture and sale of innovative medical devices, and Otsuka Pharmaceutical Factory, Inc. (OPF), global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint venture to provide additional supply chain resiliency and innovation to the North American IV solutions market.

Biotech

General

ICU Medical And Otsuka Pharmaceutical Factory A Subsidiary Of Otsuka Holdings Co. Announce Creation Of A Joint Venture To Bolster IV Solutions Manufacturing And Innovation In North America

For Fiscal Year 2024 the Company updated its estimates of GAAP net loss from a range of $(118) to $(108) to a range of $(130) to $(122) and GAAP diluted loss per share from a range of $(4.78) to $(4.38) to a range of $(5.28) to $(4.98).&nbsp;
The Company updated the estimated range of its full year 2024 guidance of adjusted EBITDA from a range of $345 million to $365 million to a range of $355 million to $365 million

ICU Medical Updates FY24 Adj EPS Outlook From $4.95 - $5.35 To $5.40 -$5.70, Est $5.22

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) reported quarterly earnings of $1.59 per share which beat the analyst consensus estimate of $1.25 by 27.2 percent. This is a 1.27 percent increase over earnings of $1.57 per share from the same period last year. The company reported quarterly sales of $589.13 million which beat the analyst consensus estimate of $574.70 million by 2.51 percent. This is a 6.47 percent increase over sales of $553.31 million the same period last year.

ICU Medical Q3 2024 Adj EPS $1.59 Beats $1.25 Estimate, Sales $589.13M Beat $574.70M Estimate

ABOS

ABSI

ACNT

AENT

AGEN

AIOT

ALTG

AMBC

AMPS

APEI

AREB

ARIS

ARMN

ATRA

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

Earnings Scheduled For November 12, 2024

Comments

ICU Medical

Intérêt court

ICU Medical (NASDAQ:ICUI) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL